Effect of ticsgrelor in conduction system of heart
Reading File
Finding Sources
Finding Sources
Searching PubMed
ticagrelor cardiac conduction bradycardia adenosine
Reading File
Finding Sources
Searching PubMed
ticagrelor adenosine reuptake heart rate ventricular pauses
Reading File
Searching PubMed
ticagrelor ventricular pauses sinus node AV block
Searching PubMed
ticagrelor bradycardia PLATO trial cardiac conduction
Reading Article
PMID: 38816988
Reading Article
PMID: 29859968
Here is a thorough synthesis of ticagrelor's effects on the cardiac conduction system:
Effect of Ticagrelor on the Cardiac Conduction System
Drug Class and Mechanism of Action
Ticagrelor (brand name Brilinta) is a direct-acting, reversible P2Y12 ADP receptor antagonist - unlike clopidogrel and prasugrel (thienopyridines), it does not require hepatic conversion to an active metabolite. It produces faster onset and more predictable inhibition of ADP-induced platelet aggregation.
A critical secondary mechanism explains its conduction effects: ticagrelor inhibits the equilibrative nucleoside transporter 1 (ENT-1), which is responsible for adenosine reuptake from the extracellular space. By blocking this transporter, ticagrelor raises extracellular adenosine concentrations.
Why Adenosine Elevation Matters for Conduction
Adenosine has well-established electrophysiologic effects on the heart, mediated via A1 receptors:
- Sinus node suppression: Adenosine activates IKAdo (acetylcholine-activated K+ current), causing hyperpolarization and slowing of spontaneous depolarization in the SA node - resulting in sinus bradycardia or sinus pauses.
- AV nodal conduction slowing: Adenosine prolongs the AV nodal refractory period, which can cause first-degree AV block, second-degree AV block, or complete (third-degree) AV block at high concentrations.
- These effects are transient due to adenosine's very short half-life in plasma, but ticagrelor-driven accumulation can sustain them.
Clinical Conduction Effects
1. Bradycardia and Ventricular Pauses
The PLATO trial (ticagrelor vs. clopidogrel in ACS) used Holter monitoring in a subset of patients at 1 month and 12 months. Ticagrelor was associated with a higher incidence of ventricular pauses >3 seconds in the first week of treatment (5.8% vs 3.6% with clopidogrel, primarily nocturnal). These were mostly asymptomatic. The PLATO trial excluded patients with sick sinus syndrome (SSS) or pre-existing high-degree AV block precisely because of this concern.
2. Dyspnea
Up to 15% of patients develop dyspnea, which is also thought to be adenosine-mediated (stimulation of pulmonary C-fibers and adenosine A2B receptors). This is the most common non-bleeding side effect and leads to drug discontinuation in approximately 0.9% of patients. - Textbook of Family Medicine 9e, p. 678
3. Heart Block
Ticagrelor can worsen pre-existing bradycardia and heart block. - Textbook of Family Medicine 9e; Braunwald's Heart Disease, 15e
PLATO Substudy: Safety in Baseline Conduction Abnormalities
A dedicated analysis of the PLATO trial ECG substudy (Scirica et al., 2018, PMID 29859968) addressed the key clinical question of whether ticagrelor is safe in patients who already have mild conduction abnormalities (sinus bradycardia, first-degree AV block, hemiblock, or bundle branch block):
- n = 15,460 (excluding pacemaker patients)
- 27.5% of patients had baseline conduction abnormalities
- The composite arrhythmic endpoint (symptomatic brady- or tachyarrhythmias, pacemaker placement, cardiac arrest) at 12 months was identical between ticagrelor and clopidogrel in both patients with and without baseline conduction disease (hazard ratio ~0.99)
- No statistically significant increase in bradycardic events with ticagrelor vs. clopidogrel, even in the conduction-abnormality subgroup
Similarly, a 2025 multicenter retrospective study (Law & Wohlfarth, PMID 38816988) comparing heart rates after inferior STEMI found no significant difference in heart rate at 48 hours between ticagrelor (76 bpm) and clopidogrel/prasugrel (73 bpm), suggesting that in real-world clinical practice, the bradycardic effect may not be clinically significant in most patients.
Contraindications / Precautions Related to Conduction
| Condition | Recommendation |
|---|---|
| Sick sinus syndrome (without pacemaker) | Avoid |
| High-degree AV block (without pacemaker) | Avoid |
| Pre-existing first-degree AV block, hemiblock, BBB | Use with caution - PLATO data suggest no excess risk vs. clopidogrel |
| Patients on other bradycardic agents (digoxin, beta-blockers, diltiazem) | Monitor closely |
Comparison with Other P2Y12 Inhibitors
| Drug | Adenosine Reuptake Inhibition | Bradycardia Risk |
|---|---|---|
| Clopidogrel | None | No |
| Prasugrel | None | No |
| Ticagrelor | Yes (via ENT-1 blockade) | Yes (adenosine-mediated) |
| Cangrelor (IV) | Yes (similar mechanism) | Similar |
Summary
The conduction effects of ticagrelor are primarily adenosine-mediated due to its inhibition of adenosine reuptake. This can cause sinus bradycardia, ventricular pauses, and exacerbation of AV nodal conduction delay. However, large RCT data (PLATO substudy) reassuringly show that even in patients with mild baseline conduction abnormalities, ticagrelor does not increase arrhythmic events compared to clopidogrel. The drug remains contraindicated in patients with sick sinus syndrome or advanced AV block without a pacemaker.
- Braunwald's Heart Disease, 15e (Braunwald's Heart Disease, Side Effects section)
- Textbook of Family Medicine 9e (p. 678)
- Scirica BM et al., PLATO conduction analysis, Am Heart J 2018 - RCT-level evidence
This is a shared conversation. Sign in to Orris to start your own chat.